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under the CC BY-NC-ND license (http:Abstract Malignant ureteral obstruction can result in renal dysfunction or urosepsis and can
limit the physician’s ability to treat the underlying cancer. There are multiple methods to deal
with ureteral obstruction including regular polymeric double J stents (DJS), tandem DJS,
nephrostomy tubes, and then more specialized products such as solid metal stents (e.g., Reso-
nance Stent, Cook Medical) and polyurethane stents reinforced with nickel-titanium (e.g.,
UVENTA stents, TaeWoong Medical). In patients who require long-term stenting, a nephrostomy
tube could be transformed subcutaneously into an extra-anatomic stent that is then inserted
into the bladder subcutaneously. We outline the most recent developments published since
2012 and report on identifiable risk factors that predict for failure of urinary drainage. These
failures are typically a sign of cancer progression and the natural history of the disease rather
than the individual type of drainage device. Factors that were identified to predict drainage
failure included low serum albumin, bilateral hydronephrosis, elevated C-reactive protein,
and the presence of pleural effusion. Head-to-head studies show that metal stents are superior
to polymeric DJS in terms of maintaining patency. Discussions with the patient should take into
consideration the frequency that exchanges will be needed, the need for externalized hard-
ware (with nephrostomy tubes), or severe urinary symptoms in the case of internal DJS. This
review will highlight the current state of diversions in the setting of malignant ureteral
obstruction.
ª 2016 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Obstruction of the ureter can be commonly caused by
advanced urological or non-urological malignant(B.H. Chew).
f Second Military Medical Univers
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//creativecommons.org/licenses/lymphadenopathy or by direct extension of the process.
Ureteral stenting can bypass the obstruction in order to
provide relief and prolong survival. Determining the cause
and level of obstruction is important to determine theity.
ion and hosting by Elsevier B.V. Ltd. This is an open access article
by-nc-nd/4.0/).
Figure 1 Resonance metallic ureteral stent (permission for
use granted by Cook Medical, Bloomington, IN, USA).
Stents for malignant ureteral obstruction 143appropriate technique for urinary diversion. Those with
malignant ureteral obstruction (MUO) have a median sur-
vival rate of 3.7e15.3 months [1]. If untreated, ureteral
obstruction can lead to renal failure and even death. Cur-
rent management options include various types of stents,
both metal and silicone, as well as nephrostomy tubes and
extra-anatomic stents. However, it is often difficult to know
which option would be most beneficial for the patient and
their potential short life expectancy. As we continue to
search for new ways to improve our techniques, we look at
minimizing stent related symptoms, ease of the procedure,
effect on quality of life (QoL), decreasing cost, and
achieving high success rates. Recent research has
addressed these issues and are the main highlights of this
review article.
2. Methods
A PubMed review of publications in the English language
was performed using the terms “metallic stents”, “tandem
stents”, “extra-anatomic stents”, “nephrostomy tubes”,
and “double J stents” published from 2012 to 2016. The
majority of studies reviewed looked at MUO however
studies investigating other etiologies were also included if
they were deemed relevant to the topic.
3. Double J stents (DJS)
The most commonly used stent type is the standard
DJS, named for its J-shaped curled ends. Manufactured
from polyurethane, silicone, or various polymers, DJS are
changed frequently at approximately 3e6 month in-
tervals, as they are prone to encrustation, obstruction,
migration, and fracture [2]. Furthermore, one of the
main problems associated with DJS is encrustation of
stone formation on the surface of the stent [2].
Polymeric stents have shown to be inferior in long-term
drainage when compared to metal stents in the setting
of MUO [2,3].4. Metallic stents
Metallic stents have become a feasible choice in the
long-term management of MUO. Different types of
metallic stents exist including the non-expandable coiled
metallic Resonance stent (Cook Medical, Bloomington,
IN, USA), the thermo-expandable metal alloy Memokath
051 stent (PNN Medical, Glostrup, Denmark), and
the self-expandable covered metallic UVENTA stent
(Taewoong Medical, Gojeong-ro, Wolgot-myeon, Gimpo-
si, Gyeonggi-do, South Korea).
The Resonance stent is a nickelecobaltechromiume
molybdenum alloy DJS [2] (Fig. 1). This stent does not have
a lumen like the Memokath 051 and UVENTA stents;
therefore, insertion of the stent is done through the lumen
of a 10 Fr ureteric catheter under fluoroscopic guidance [4].
Outcomes from studies utilizing metal stents are shown in
Table 1.
The Memokath 051 stent is composed from a nickel-
titanium alloy that forms a tight spiral structure [5] (Fig. 2).Regulating the temperature of the stent during insertion and
removal is important for proper use of this stent [4].
Expertise is required to place the Memokath 051 stent, as
insertion can be complicated and technically challenging [2].
Its coiled structure prevents urothelial ingrowth, preserves
peristalsis, and reduces the risk of secondary ischemic
damage to the ureteric wall [5].
Two layers of a self-expandable nickel-titanium alloy
mesh covering a polytetrafluoroethylene (PTFE) layer
combine to make the UVENTA stent (Fig. 3). The outer mesh
containing a nickel-titanium skeleton holds the stent
against the ureteral urothelium preventing stent migration
[5]. The inner PTFE and mesh layers prevent tissue ingrowth
and maintain patency by strengthening the overall radial
force of the stent.
Kim et al. [5] were the first to publish a study comparing
the UVENTA and Memokath 051 stents in 27 patients. Both
types of stents demonstrated similar minor complications
when used for both benign and MUO. However, the clinical
success rate (defined as improved renal function and no
obstruction on intravenous urography, computed tomogra-
phy, or diuretic renography) of the UVENTA stent was
significantly higher than the Memokath 051 stent (82.4% vs.
42.9%, respectively; p Z 0.031). The difference with suc-
cess rate further increased when comparing just malignant
obstruction (92% UVENTA vs. 33% Memokath 051;
p Z 0.022). Failures in the Memokath 051 group included
tumor progression, and stent migration. Failures in the
UVENTA group included stent migration and mucosal hy-
perplasia causing luminal obstruction. Migration of the
Memokath 051 was the biggest reason for differences be-
tween the two stentsdall other failure reasons were equal
between the two groups. Shortcomings of this study include
the fact that these patients were retrospectively analyzed,
the short-term follow-up, and the small sample size. The
Memokath 051 and UVENTA had mean indwelling times of
13.6 months (range, 7e21 months) and 12 months (range,
9e16 months), respectively. The small sample size pre-
cludes the authors from definitively identifying which fac-
tors predicted long-term success.
Kadlec et al. [6] performed a retrospective study on 47
patients with chronic ureteral obstruction and examined
their results over a 5-year follow-up period. They found the
Table 1 Summary of studies evaluating metal ureteral stents.
Author Type Year Total
patients
Etiology Total
stents
Mean duration
(month)
Median
duration
(month)
Type of stent Mean age
(year)
Failure (%) Success (%)
Chow et al. [26] Retrospective 2014 79 Cancer patients with
MUO
117 N/A 5.77 Resonance 59.9 N/A N/A
Chow et al. [3] Retrospective 2015 42 Cancer patients with
MUO
50 N/A 5.3 Resonance 57.2 N/A N/A
Abbasi et al. [8] Prospective 2013 20 Advanced cancer and
MUO
27 7.4 N/A Resonance 49.9 40 N/A
Chow et al. [7] Retrospective 2014 74 Non-urological MUO 113 N/A 6.2 Resonance 57.4 N/A 86.9
Kadlec et al. [6] Retrospective 2013 47 Benign and MUO e
chronic ureteral
obstruction
139 19.5 13 Resonance 62 28 N/A
Taylor et al. [19] Prospective 2012 21 Benign and MUO e
chronic ureteral
obstruction
N/A N/A 12 Resonance 70.6 N/A 95
Baumgarten et al.
[21]
Retrospective 2014 50 Chronic ureteral
obstruction
due to MUO, cutaneous
ureterostomies, or ileal
conduit
97 N/A 9.48 Resonance 63.0 8.2 N/A
Frederick et al. [20] Retrospective 2016 86 Benign and MUO 230 20 7.4 Resonance 66 N/A N/A
Kim et al. [5] Retrospective 2014 27 Benign and MUO N/A 13.6
Memokath/
12 UVENTA
N/A Memokath/
UVENTA
60
Memokath/
56 UVENTA
57.1
Memokath/
17.6 UVENTA
42.9
Memokath/
82.4 UVENTA
Kim et al. [18] Retrospective 2015 40 Non-urological MUO 40 N/A 7.89 UVENTA 56.0 N/A 77.5
Chung et al. [2] Prospective 2014 32 Cancer patients with
MUO
N/A N/A N/A UVENTA 50.9 35 N/A
Chung et al. [17] Retrospective 2013 54 MUO 71 N/A 3.22 UVENTA 57 N/A 81.7
MUO, malignant ureteral obstruction.
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Figure 3 UVENTA ureteral stent (permission for use granted
by TaeWoong Medical Co. Ltd., Gojeong-ro, Wolgot-myeon,
Gimpo-si, Gyeonggi-do, South Korea).
Figure 2 Memokath 051 ureteral stent (permission for use
granted by PNN Medical, Glostrup, Denmark).
Stents for malignant ureteral obstruction 145median stenting duration for benign and malignant
obstruction to be 22 months and 7 months, respectively
(p Z 0.106). The mean stenting duration was 8 months for
the Resonance stent before they were exchanged. The most
common reason for early exchange was stent-related uri-
nary tract infection (UTI). The majority (57%) of the pa-
tients were stented for MUO. They had 28% failure rate,
with majority of these stents failing relatively soon after
placement with a mean follow-up of 20 months. The au-
thors did not find any pre-stent factor that was significantly
associated with failure. Unlike previous studies, they found
no difference between the results of patients requiring the
metal stent for malignant or benign ureteral obstructions.
Chow et al. [7] reported similar results for their 74 pa-
tients who received the metallic Resonance stent for non-
urological malignant diseases and MUO. The median func-
tional duration was 6.2 months. Their success rate of
insertion was 86.9% of which 91.2% achieved patency of the
urinary system. Risk factors for stent failure were ob-
structions in the abdominal ureter (irregular thickening of
the ureteral wall with abnormal enhancement and infil-
tration) and lymphatic metastasis around the ureter
(p Z 0.0279 and 0.0398, respectively). Non-urological
cancers have a lower risk of stent failure than urological
cancers. No major complications were reported however
minor complications such as UTIs, gross hematuria, dysuria,
flank pain, urinary frequency, and stent migration,
occurred. The Resonance stent was inserted in these pa-
tients only after they failed a regular polymeric DJS. The
authors hypothesize, this delayed time to obtaining the
Resonance may have resulted in cancer progression and a
more difficult patient population in which to stent. Another
study demonstrated similar positive results of the Reso-
nance stent in patients with advanced cancer and MUO with
a mean time to failure of 7.4 months [8].
These studies cannot be directly compared due to
different patient populations, sample sizes, and etiologies,
but a common trend is that metallic stents remain patent for
a longer dwell time, thus eliminating the need for more
frequent changes. Metal stents are also well tolerated with
minimal lower urinary tract symptoms. Although the pur-
chase price of each metal stent may be more costly than a
regular polymeric stent, itmay result in overall cost savings if
the number of visits to the operating room can be reduced.5. Tandem stents
Inserting tandem ureteral stents, also known as twin ure-
teral stents, can be considered an alternative to the single
DJS. In addition to an extra lumen, the side-by-side stents
are thought to increase drainage as the second stent creates
additional space between the two stents and the ureteral
wall even if there is external compression.
Two studies have shown the effectiveness of tandem
stents in patients with MUO. The first was a retrospective
analysis of 187 cases in 66 patients, the largest experience
with tandem ureteral stents to date [9]. Tandem stents
were inserted for both MUO and benign ureteral obstruction.
The mean stent duration in these patients was 4.8 months.
No complications were identified in their cohort and stent
irritation occurred in 12 of the patients. Their results sug-
gested tandem stent placement was highly successful in
both benign and MUO. Patients with MUO had an approxi-
mated survival of 1 year, with the likelihood of mortality and
shorter overall survival increasing with stent failures: 71% of
patients with MUO and previous stent failure died at a me-
dian 66 days, whereas 40% of patients with MUO and without
stent failure died at a median 433 days. Stent failure was a
prognostic factor for mortality and likely a sign of cancer
progression in those patients.
The second study prospectively performed 22 tandem
ureteral stent insertions in 15 patients with MUO [10]. They
also found that patients with failing tandem ureteral stents
had a shorter life expectancy than those with functioning
tandem stents (median life expectancy of 45.6 days vs.
162.5 days, respectively; p < 0.05). Overall, they deter-
mined tandem stents can be an effective method of man-
aging MUO in patients where a single DJS had previously
failed [10]. In both these studies, the patient mortality was
almost certainly due to progression of the cancer, which
resulted in failure of the stents to drain.
6. Nephrostomy tube
Percutaneous nephrostomy (PCN) tube insertion is a mini-
mally invasive procedure that can be performed under local
anesthesia by interventional radiologists or urologists.
Complications that can occur during this procedure are
146 K. Pavlovic et al.bleeding, bowel transgression, sepsis, and pleural compli-
cations [11]. It is an effective way of relieving ureteric
obstruction and pain. However, the external drainage tube
and bag can be burdensome, restrict physical activity, and
negatively impact the patient’s QoL. Complaints regarding
PCN include impaired body image, social dysfunction, and
compromised sleep (especially with bilateral PCN) [12].
Minor complications resulting from the PCN tube include
pain, dislodgment, blockage, infection, and frequent tube
changes in addition to the routine 3-month changes [13].
Monsky et al. [13] prospectively evaluated the effect
placement of PCN tube (Boston Scientific, Natick, MA, USA),
an internal DJS (Boston Scientific), or an internaleexternal
nephroureteral stent (Boston Scientific) for MUO had on QoL
in 46 patients. Patients were not randomized to a specific
intervention. A previously validated QoL survey, which
included questions from a published survey specific to
nephrostomy and nephroureteral stents, was taken at 7, 30,
and 90 days after placement. A common validated health
index, to assess physical, social, functional, and emotional
well-being was also included. The results indicated no sig-
nificant difference in QoL between the three interventions.
Urinary symptoms and pain, including dysuria and urinary
frequency, in those receiving DJSwere significantly higher at
30 and 90 days that those with nephrostomies (p Z 0.0035
and p Z 0.0189, respectively), but not at 7 days after
placement. Greatest use of pain medications at 30 and 90
days was seen in the DJS group (p Z 0.0189). DJS related
procedures also required significantly longer fluoroscopy
time (p Z 0.0054). There was no significant difference in
UTIs and use of antibiotics between the groups (p > 0.05).
Routine changes were scheduled at 3-month intervals;
however, due to a greater rate of complications, patients
with nephrostomy tubes required more additional changes
than DJS and internaleexternal nephroureteral stent
(p Z 0.051). A total of 83% of nephrostomy tubes, 36% of
nephroureteral stents, and 16% of DJSwere changed because
of complications. Patients should be counseled regarding
these symptoms when making a decision regarding the type
of diversion they will receive.
Alawneh et al. [12] also updated and validated a prog-
nostic model developed by Ishioka et al. [14] which predicts
the overall survival in cancer patients after receiving PCN.
PCN was performed in 211 patients with MUO. Statistically
significant factors that predicted shorter survival after PCN
included type of malignancy, presence of metastasis to any
site, presence of pleural effusion, bilateral hydronephrosis,
and low serum albumin < 3.5 mg/dL. Patients were further
categorized into four risk groups depending on the number of
these factors were present. Those with 0, 1, 2, and 3 risk
factors had a median survival of 17.64, 7.7, 2.20, and 1.72
months, respectively (p < 0.0001). The median survival rate
for all patientswas 5.05months and 87%of the patients in the
study were deceased by the end of the observation period
illustrating the severity of the effects of the malignancies
rather than the typeof urinary diversion patients underwent.
Azuma et al.’s retrospective study [15] also looked at
factors that predicted poor prognosis for advanced cancer
patients with MUO. A multivariate analysis compiled from
214 patients, found that low albumin, low sodium, and high
C-reactive protein in the serum before PCN were associated
with poor prognosis (p < 0.0001). Three or more clinicalevents related to malignant dissemination before PCN was
also another indicator of poor prognosis (p < 0.0001). De-
gree of hydronephrosis was not an indicator in this study,
but was shown to be an indicator in other studies described
above [12]. When divided into three risk groups, the median
survival in the favorable (0 or 1 risk factor), intermediate (2
risk factors), and poor (3 or 4 risk factors) risk factor groups
was 12.0, 6.0, and 2.8 months, respectively (p < 0.0001).
The median overall survival was 6.4 months. The authors
suggest examining these levels to ensure the patient is
appropriately informed before making a decision on
whether to have a PCN placed.
7. Extra-anatomic stent (EAS)
An EAS is an internal prosthetic replacement of the
ureter, which allows urine drainage by bypassing the
obstruction. It involves a PCN that is then tunneled
subcutaneously along the abdomen and then inserted
into the antero-superior portion of the bladder via cys-
totomy. None of the tubing is externalized and is all
subcutaneous. This is a viable long-term option for pa-
tients who are too frail to undergo reconstruction surgery
or do not want to do so [16]. The primary candidates
were those where previous stents or nephrostomy had
failed. EAS is also used in transplanted kidneys and ileal
conduits.
Thenormalpractice forKimuli et al. [16]was toutilize two
types of stents. The first was a short-term 8.5 Fr 65 cm EAS
with side holes at either end. If thepatient survived andhada
good prognosis after the use of first stent, a longer-term 29 Fr
detour EAS would be used at the exchange. This second
procedure has the potential of being a permanent solution,
but requires open cystostomy, which is more invasive.
Therefore, it is generally only considered the primary option
for those with a longer life expectancy. Contraindications
included uncorrected coagulopathies, tumor invasion along
the stent, and active malignancy either arising or invading
the bladder. Stent placement near a tumor is not advised as
tumor seeding along the stent may occur. Both stent
blockage and storage bladder symptoms were rare. Other
complications include encrustation, infection, obstruction,
or skin problems. One case presented with skin erosion, and
two others had local tumor progression with bladder fistulae
resulting in the removal of the stent.
With experience in over 100 patients at their institution,
Kimuli et al. [16] determined that EAS offers a minimally
invasive way to provide a temporary or permanent solution
for internal urinary drainage. EAS was determined to be an
alternative to a long-term nephrostomy tube, with the tubes
being routinely changed at 12 months.
8. Metallic stents vs. plastic double J stents
When comparing the Resonance metallic ureteral stent to a
regular polymeric stent in patients with MUO, Chow et al.
[3] demonstrated a mean increase in functional duration of
4 months using the Resonance stent (p < 0.0001). In this
retrospective study, 42 patients who had previously failed
polymeric stents had their stent replaced with the Reso-
nance stent. The degree of hydronephrosis was measured
Stents for malignant ureteral obstruction 147both prior to the placement of the polymeric stents and
prior to the placement of the Resonance stent. Hydro-
nephrosis and serum creatinine subsided or remained the
same in 90% of these patients. Stent duration was not
affected by severe hydronephrosis, suggesting the Reso-
nance stent was more effective in relieving severe
obstruction. No major complications were reported and no
stents were exchanged due to non-tolerability. A few pa-
tients had minor complications that were similar to those
seen with the polymeric stents. These included dysuria,
fever, urinary frequency, flank pain, and hematuria. Pre-
operative serum creatinine < 2 mg/dL, age  60 years,
gender, method of insertion (antegrade vs. retrograde),
previous technical failure, genitourinary (GU) cancer,
previous and ongoing radiotherapy, severe hydronephrosis,
and occurrence of UTI were analyzed to determine if they
were associated with good stent outcomes. Radiotherapy,
GU cancer, and UTI were not associated with reduction of
stent duration. Pre-operative serum creatinine < 2 mg/dL
was determined to be the only significant indicator of good
stent outcome. Where prior polymeric stents failed, the
Resonance stent presented an effective and safe method of
relieving MUO [3].
Chung et al. [2] compared the UVENTA stent to the
standard polymeric DJS [2]. Data were prospectively
collected from 32 patients with the UVENTA stent inserted
and compared to data retrospectively collected from 56
patients with DJS. Both stents were placed for MUOs caused
by various cancers. Minor complications included mild pain,
hematuria, and UTIs in both groups. Stent migration only
occurred in one UVENTA patient. Primary patency was
defined as the time between the initial insertion of the
stent and secondary procedure to ensure there was urinary
drainage. Assisted primary patency was defined as the time
between the initial insertion and repeat PCN. They found
that the primary patency of the UVENTA stent was better
than the assisted patency of DJS (p Z 0.012). In terms of
patency and technical success, the UVENTA stent was
determined to be superior to DJS. This study was not a
randomized control study, but an effective method of uri-
nary decompression similar to a previous study showing that
the UVENTA stent was safe and effective in palliative
treatment of MUO [17].
In a retrospective study of 40 patients, Kim et al. [18]
established that long-term indwelling of DJS affected the
subsequent UVENTA stent failure rate through their multi-
variate analysis of potential risk factors (p Z 0.037). They
suggested this might be due to the anatomical, histological,
and functional changes that are induced with long-term
DJS. Other risk factors such as age, serum creatinine level
at the time of stent placement, and history of previous
radiation therapy were not statistically significant risk
factors of UVENTA stent failure.
Standard polymer DJS are unable to provide the long-
term drainage seen with metal stents [2e4]. Therefore,
unlike metal stents, polymeric or silicone stents are
changed regularly at 3e6 month intervals, necessitating a
minimum of two to four exchanges per year [19]. This has a
substantial effect on the annual cost for caring for these
patients. Polymer stents are also prone to recurrent ste-
nosis as a result of compression from advanced malignancy,
retroperitoneal metastases, or encrustation. Metal stentsare able to resist lumen occlusion from extrinsic compres-
sion, allowing for the longer indwelling times.
According to a prospective study of 21 Resonance stent
and 15 polymer stented patients, the mean charges for a
single polymer stent and metal stent change are
US$6072.75 and US$9469.50, respectively [19]. The prices
include hospital charges related to stent cost and surgery,
including anesthesia, fluoroscopy, pharmaceuticals, and
surgeon charges. Annually, the price range for a polymer
stent change was estimated to be between
US$18,218.25eUS$36,436.50. The cost depends on the
number of exchanges that occur within a year, with the
lower end at three exchanges and the upper end at six
exchanges annually. A significant financial reduction by
48%e74% occurs when compared to the annual price of a
metal stent. This cost analysis excluded patients with a life
expectancy of less than 6 months. The median duration of
the Resonance stent was 12 months (range, 2e32 months).
With the exception of one patient, the resonance stent was
tolerated well and no removals or shortening of the
indwelling period were required. Overall, success rate of
this cohort was 95%. There is a significant financial benefit
to having a metal stent able to last 12 months without the
risk of encrustation or failure from extrinsic compression
[19].
Similarly, Frederick et al. [20] calculated an overall 48%
annual cost reduction compared to regular polymeric stent
changes. Eighty-six patients had either malignant or benign
ureteral obstruction and underwent unilateral or bilateral
metal stent placement. The annual cost of unilateral polymer
placement at 3 and 6 months was determined to be
US$16,933.45 and US$8171.00, respectively. Annual cost for
metal stents based onmean indwelling duration of 7.4months
was US$7859.43. Operating room, anesthesia, medications,
fluoroscopy, and stent costs were included. Intangible costs,
such as loss of work and productivity were not included in the
analyses, but should be considered as a societal cost.With the
inclusion of average loss of wages in their calculation, Baum-
garten et al. [21] calculated an even greater cost reduction of
up to 59.5%annuallywith the use of theResonance stentwhen
compared toDJS. Their cohort of 50 patients had a failure rate
of 8.2% and median stent life of 288.4 days.
Wijayarathna et al. [22] analyzed data on 82 patients who
underwent retrograde ureteric stenting for ureteric obstruc-
tion related to malignant lesions. They determined elevated
serum creatinine over 3 mg/dL and CT evidence of tumor
recurrence in the pelvis (p Z 0.004 and p Z 0.026, respec-
tively) were indicators of poor outcome. Even if stenting was
successful, these patients had a short life expectancy.9. Nephrostomy tube vs. double J stent
A prospective study by Garg et al. [23] compared the
nephrostomy tube and DJS in open pyeloplasty for ureter-
opelvic junction obstruction hydronephrosis of 40 children
ages 2 months to 12 years. Although this study did not study
MUO, we wanted to illustrate a head-to-head study of PCN
vs. DJS. Minor complications seen in DJS for this study
included UTI, increased urinary frequency, distal protrusion
into posterior urethra, and dysuria. Other complications
that can result from a DJS are mild to moderate flank pain,
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gency, bladder spasm, hematuria, mild pelvic discomfort,
urinary urgency, encrustation, pyelonephritis, and inconti-
nence. One major complication that occurred for the DJS
group was proximal migration with urinoma formation.
Stent migration into the urethra past the external sphincter
can result in incontinence.
The authors noted that the optimal stent length could
avoid several post-operative problems secondary to
migration and bladder irritation. The formula proposed to
determine length was:
Length of DJS ðcmÞZLength of retained ureter ðcmÞ  2
Minor complications seen in the PCN group include
tube blockage, urinary leakage a few days after tube
removal, persistent urine leak after tube removal, and
increased urinary frequency. Breakage of the tube during
removal in one patient was the only major complication
with the PCN group. Drainage function in both groups
showed similar improvement. Those with nephrostomy
tubes had a longer hospital stay (3e25 days for DJS group
vs. 10e16 days for PCN group; pZ 0.001); however, they
incurred an overall lower cost as DJS require removal
under anesthesia, resulting in an overall higher mean
cost. Patients with nephrostomy tubes preferred to have
the tubes removed before discharge due to travel cost
and fear of dislodgement.
Song et al. [24] performed a retrospective study
reviewing 87 patients bilaterally stented for malignant
bilateral ureteral obstruction. If internal stenting failed,
the patient was converted to PCN. Twelve of the patients
had PCN conversion. Of these, eight had early PCN con-
version (<1 year after initial stent) and four had late PCN
conversion (after the patient progressed into chronic kid-
ney disease stage 4 or 5) or no conversion. Although a
relatively small population was used, they determined that
PCN conversion prior to the patient progressing to chronic
kidney disease stage 4 or 5, caused a better renal function
outcome, than those who had late PCN conversion
(pZ 0.061). This was especially important in patients over
the age of 55 years, with diabetes, or poor baseline renal
function. Other studies however suggest that PCN place-
ment does not prolong survival for patients with advanced
cancer [25]. Cancer status was the most causative factor
related to stent failure in this study [24].
10. Nephrostomy tube vs. extra anatomic stent
Palliative urinary diversions can be done by either PCN or
EAS. The difference is that the nephrostomy tube drains
through an external bag, whereas an EAS is internal. PCN
tubes are placed in situations where EAS and other pro-
cedures have failed. For the insertion of an EAS, a new or
existing nephrostomy tract can be used. Therefore, these
two interventions can be done in sequence. Patients are
usually discharged the day of surgery or the following
day. The EAS procedure is not without its faults and it can
be time-consuming, and cumbersome for the patient.
Stent implantation can also be challenging. Kimuli et al.
[16] followed 27 patients for 12 months and noticed animprovement in the mean QoL from 3.4  1.4 preopera-
tively to 7.6  1.0 postoperatively.
Nephrostomy tubes are changed regularly at 3 months,
which is significantly shorter than the 12 months an EAS can
stay indwelling. The mean duration for an EAS was 7.5
months (range of 3e18 months) [16]. Due to the external
method of drainage in PCN the QoL of the patient is
compromised. Therefore, PCN is not ideal for long-term
treatment and consideration should be given for changing
to an EAS.11. Factors predicting stent failure
11.1. Metal stent
Possible risk factors for Resonance stent failure include
age, sex, degree of hydronephrosis, treatment for cancer,
occurrence of UTI, serum creatinine, and cancer type. Of
these, age  60 years and serum creatinine level  2 mg/dL
were associated with shorter stent duration [26]. In this
retrospective study, 117 Resonance stents where placed in
79 cancer patients with MUO. When age and serum creati-
nine level were controlled for, lower gastrointestinal (GI)
cancer showed a lower risk of stent failure than GU cancer
(p Z 0.0494). Therefore, cancer type may also be a sig-
nificant indicator. They hypothesized that lower GI cancers
reduce the compression on the stent as they have softer
texture and composition. Overall, lower GI cancer, younger
age, and low serum creatinine levels are good indicators to
stent. Stent failure due to high pre-operative serum
creatinine may be a result of poor urine production pro-
moting encrustation and thus shortening the stent duration.
The median duration of the resonance stent in this study
was 5.77 months. Insertion of metal stent was done after
the regular polymeric stent failed. This could be the reason
for the shorter stent duration seen in this study, as hydro-
nephrosis had already developed and the cancer likely
progressed. The authors found that neither severe hydro-
nephrosis nor peritoneal carcinomatosis were associated
with stent failure. However, increased level of obstruction
was associated with stent failure. Since the Resonance
stent in this study was not inserted as soon as hydro-
nephrosis developed, there is a potential selection bias in
this cohort.11.2. Regular polymeric stent
Yu et al. [1] assessed performance status, type of cancer,
hydronephrosis grade location of the obstruction, presence
of bladder invasion, C-reactive protein, serum albumin, and
inflammation-based prognostic score (Glasgow prognostic
score, GPS) of the cystoscopic ureteral stent (Endo-sof,
Cook Urological, Spencer, IN, USA). They performed a
retrospective study including 71 patients with MUO due to
nonurological cancers undergoing stent placement. Ac-
cording to their multivariate analysis, preoperative serum
creatinine level of >1.2 mg/dL, GPS  1, and presence of a
mid or lower ureteral obstruction (over or below the
sacroiliac joint) were associated with shorter stent duration
(p Z 0.044, 0.001, and 0.007, respectively). The median
Stents for malignant ureteral obstruction 149stent survival and overall survival were 5 and 7.7 months,
respectively.
12. Conclusion
MUO can be handled by DJS, tandem DJS, PCN tubes, metal
ureteral stents, or EAS. The predictors of failure are those of
advanced cancer progression. The QoL between modalities is
similar and consideration must be given to the frequency of
exchange, the cost of exchange procedures, and the dif-
ference in urinary symptoms between the different modal-
ities. None of these have been shown to completely extend
the life of patients (from cancer), but do preserve renal
function in order for them to receive treatment modalities
such as chemotherapy or surgery. The modalities available to
physicians are varied and depend on access to each modality
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